These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25175016)

  • 21. Surfactant Impact on Interfacial Protein Aggregation and Utilization of Surface Tension to Predict Surfactant Requirements for Biological Formulations.
    Vargo KB; Stahl P; Hwang B; Hwang E; Giordano D; Randolph P; Celentano C; Hepler R; Amin K
    Mol Pharm; 2021 Jan; 18(1):148-157. PubMed ID: 33253579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method.
    Honemann MN; Wendler J; Graf T; Bathke A; Bell CH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():1-8. PubMed ID: 30951966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An Approach to Mitigate Particle Formation on the Dilution of a Monoclonal Antibody Drug Product in an IV Administration Fluid.
    Zheng S; Adams M; Mantri RV
    J Pharm Sci; 2016 Mar; 105(3):1349-50. PubMed ID: 26886343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polysorbate degradation in biotherapeutic formulations: Identification and discussion of current root causes.
    Dwivedi M; Blech M; Presser I; Garidel P
    Int J Pharm; 2018 Dec; 552(1-2):422-436. PubMed ID: 30300706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gelation of a monoclonal antibody at the silicone oil-water interface and subsequent rupture of the interfacial gel results in aggregation and particle formation.
    Mehta SB; Lewus R; Bee JS; Randolph TW; Carpenter JF
    J Pharm Sci; 2015 Apr; 104(4):1282-90. PubMed ID: 25639229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edetate Disodium as a Polysorbate Degradation and Monoclonal Antibody Oxidation Stabilizer.
    Yarbrough M; Hodge T; Menard D; Jerome R; Ryczek J; Moore D; Baldus P; Warne N; Ohtake S
    J Pharm Sci; 2019 Apr; 108(4):1631-1635. PubMed ID: 30502482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced Subvisible Particle Formation in Lyophilized Intravenous Immunoglobulin Formulations Containing Polysorbate 20.
    Zhou C; Qi W; Lewis EN; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Aug; 105(8):2302-9. PubMed ID: 27290624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
    Doshi N; Martin J; Tomlinson A
    Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
    Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
    J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Comprehensive Assessment of All-Oleate Polysorbate 80: Free Fatty Acid Particle Formation, Interfacial Protection and Oxidative Degradation.
    Doshi N; Giddings J; Luis L; Wu A; Ritchie K; Liu W; Chan W; Taing R; Chu J; Sreedhara A; Kannan A; Kei P; Shieh I; Graf T; Hu M
    Pharm Res; 2021 Mar; 38(3):531-548. PubMed ID: 33713012
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metal-Induced Fatty Acid Particle Formation Resulting from Hydrolytic Polysorbate Degradation.
    Gregoritza K; Cai SK; Siketanc M; Woehr A; Lebouc V; Kishore RSK; Nicoulin V; Bleher S; Allmendinger A
    J Pharm Sci; 2022 Mar; 111(3):743-751. PubMed ID: 34600939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polysorbate 20 prevents the precipitation of a monoclonal antibody during shear.
    Patapoff TW; Esue O
    Pharm Dev Technol; 2009; 14(6):659-64. PubMed ID: 19883255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new mechanism for decreasing aggregation of recombinant human interferon-gamma by a surfactant: slowed dissolution of lyophilized formulations in a solution containing 0.03% polysorbate 20.
    Webb SD; Cleland JL; Carpenter JF; Randolph TW
    J Pharm Sci; 2002 Feb; 91(2):543-58. PubMed ID: 11835212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monitoring polysorbate hydrolysis in therapeutic proteins using an ultrasensitive extraction-free fatty acid quantitation method.
    Zhang S; Riccardi C; Kamen D; Xiao H; Li N
    Anal Biochem; 2022 Jan; 637():114472. PubMed ID: 34801481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Surface activity of a monoclonal antibody.
    Mahler HC; Senner F; Maeder K; Mueller R
    J Pharm Sci; 2009 Dec; 98(12):4525-33. PubMed ID: 19655376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multivariate design for the evaluation of lipid and surfactant composition effect for optimisation of lipid nanoparticles.
    Martins S; Tho I; Souto E; Ferreira D; Brandl M
    Eur J Pharm Sci; 2012 Apr; 45(5):613-23. PubMed ID: 22245538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
    Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
    J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein-Polydimethylsiloxane Particles in Liquid Vial Monoclonal Antibody Formulations Containing Poloxamer 188.
    Grapentin C; Müller C; Kishore RSK; Adler M; ElBialy I; Friess W; Huwyler J; Khan TA
    J Pharm Sci; 2020 Aug; 109(8):2393-2404. PubMed ID: 32194095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.